Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
On December 27, 2021, the FDA approved Otsuka Pharmaceutical’s Rexulti (brexpiprazole), for the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
